These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 33773495)
21. Consensus to identify the dangerous drugs risks in hospital pharmacy services. Bernabeu-Martínez MÁ; García-Salom P; Burgos-San José A; Navarro-Ruiz A; Sanz-Valero J; Wanden-Berghe C Farm Hosp; 2020 Mar; 44(2):51-61. PubMed ID: 32452316 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of surface contamination in a hospital hematology--oncology pharmacy. Touzin K; Bussières JF; Langlois E; Lefebvre M J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214 [TBL] [Abstract][Full Text] [Related]
23. Safe procedure development to manage hazardous drugs in the workplace. Gaspar Carreño M; Achau Muñoz R; Torrico Martín F; Agún Gonzalez JJ; Sanchez Santos JC; Cercos Lletí AC; Ramos Orozco P Farm Hosp; 2017 Mar; 41(2):222-256. PubMed ID: 28236799 [TBL] [Abstract][Full Text] [Related]
24. Retail clinics colocated with pharmacies: A Delphi study of pharmacist impacts and recommendations for optimization. Knapp KK; Olson AW; Schommer JC; Gaither CA; Mott DA; Doucette WR J Am Pharm Assoc (2003); 2020; 60(2):311-318. PubMed ID: 31126829 [TBL] [Abstract][Full Text] [Related]
25. The application of novel field measurement and field evaluation protocols for assessing health care workers' exposure risk to antineoplastic drugs. Astrakianakis G; Jeronimo M; Griffiths A; Colombo M; Kramer D; Demers PA; Hon CY J Occup Environ Hyg; 2020 Sep; 17(9):373-382. PubMed ID: 32615872 [TBL] [Abstract][Full Text] [Related]
26. Consensus conference. Rehabilitation of persons with traumatic brain injury. NIH Consensus Development Panel on Rehabilitation of Persons With Traumatic Brain Injury. JAMA; 1999 Sep; 282(10):974-83. PubMed ID: 10485684 [TBL] [Abstract][Full Text] [Related]
27. Mapping the route to medication therapy management documentation and billing standardization and interoperabilility within the health care system: meeting proceedings. Millonig MK J Am Pharm Assoc (2003); 2009; 49(3):372-82. PubMed ID: 19357067 [TBL] [Abstract][Full Text] [Related]
28. Patient characteristics associated with multiple pharmacy use in the U.S. population: Findings from the Medical Expenditure Panel Survey. Look KA Res Social Adm Pharm; 2015; 11(4):507-16. PubMed ID: 25453538 [TBL] [Abstract][Full Text] [Related]
29. The Safety of Intravenous Drug Delivery Systems: Update on Current Issues Since the 2009 Consensus Development Conference. Rodriguez R Hosp Pharm; 2018 Dec; 53(6):408-414. PubMed ID: 30559529 [TBL] [Abstract][Full Text] [Related]
30. Addition of a Novel Qualitative Technique to Standard Quantitative Practices for Evaluation of Hazardous Drug Exposure in a Canadian Hospital Setting. Grewal R; Karas A; Goyal S Can J Hosp Pharm; 2024; 77(3):e3509. PubMed ID: 38988871 [TBL] [Abstract][Full Text] [Related]
31. Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process. Power LA; Sessink PJ; Gesy K; Charbonneau F Hosp Pharm; 2014 Apr; 49(4):355-62. PubMed ID: 24958942 [TBL] [Abstract][Full Text] [Related]
32. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Hedmer M; Georgiadi A; Bremberg ER; Jönsson BA; Eksborg S Ann Occup Hyg; 2005 Oct; 49(7):629-37. PubMed ID: 16126760 [TBL] [Abstract][Full Text] [Related]
33. Pharmaceutical counseling: Between evidence-based medicine and profits. Egorova SN; Akhmetova T Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727 [TBL] [Abstract][Full Text] [Related]
34. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. Siderov J; Kirsa S; McLauchlan R J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of Current Hazardous Drug Exposure Control in Community Pharmacy. Papastergiou J; Smiley T J Pharm Technol; 2022 Jun; 38(3):155-158. PubMed ID: 35600277 [No Abstract] [Full Text] [Related]
36. Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis. Arch Intern Med; 1999 Jul; 159(14):1529-39. PubMed ID: 10421275 [TBL] [Abstract][Full Text] [Related]
37. NIH State-of-the-Science Conference Statement on preventing violence and related health-risking social behaviors in adolescents. NIH Consens State Sci Statements; 2004 Oct 13-15; 21(2):1-34. PubMed ID: 17308550 [TBL] [Abstract][Full Text] [Related]
38. Current practices in the delivery of pharmacogenomics: Impact of the recommendations of the Pharmacy Practice Model Summit. Valgus J; Weitzel KW; Peterson JF; Crona DJ; Formea CM Am J Health Syst Pharm; 2019 Apr; 76(8):521-529. PubMed ID: 31361863 [TBL] [Abstract][Full Text] [Related]
39. NIH State-of-the-Science Conference Statement on improving end-of-life care. NIH Consens State Sci Statements; 2004 Dec 6-8; 21(3):1-26. PubMed ID: 17308546 [TBL] [Abstract][Full Text] [Related]
40. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists. Kirschenbaum BE Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S13-20. PubMed ID: 19966075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]